These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 9217779)
21. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting. Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924 [TBL] [Abstract][Full Text] [Related]
22. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Lewis RJ; Lipsky AM; Berry DA Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241 [TBL] [Abstract][Full Text] [Related]
23. Quantifying and documenting prior beliefs in clinical trials. Chaloner K; Rhame FS Stat Med; 2001 Feb; 20(4):581-600. PubMed ID: 11223902 [TBL] [Abstract][Full Text] [Related]
24. Bayesian stopping rules for trials. Kulvichit K Lancet; 2002 Jan; 359(9300):77. PubMed ID: 11809215 [No Abstract] [Full Text] [Related]
30. An orwellian discourse on the meaning and measurement of noninferiority. Diamond GA; Kaul S Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435 [TBL] [Abstract][Full Text] [Related]
31. Bayesian methods for design and analysis of safety trials. Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858 [TBL] [Abstract][Full Text] [Related]
32. Believability of clinical trials: a diagnostic testing perspective. Lauer MS J Thorac Cardiovasc Surg; 2006 Aug; 132(2):249-51. PubMed ID: 16872945 [No Abstract] [Full Text] [Related]
33. n-of-1 trials and their combination: suitable approaches for CAM research? Hart A; Sutton CJ Complement Ther Med; 2003 Dec; 11(4):213-4. PubMed ID: 14969791 [No Abstract] [Full Text] [Related]
34. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups. Kikuchi T; Gittins J Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784 [TBL] [Abstract][Full Text] [Related]
35. Classic or Bayesian research design and analysis. Does it make a difference? Bloom BS; de Pouvourville N; Libert S Int J Technol Assess Health Care; 2002; 18(1):120-6. PubMed ID: 11987435 [TBL] [Abstract][Full Text] [Related]
37. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Schmidli H; Bretz F; Racine-Poon A Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875 [TBL] [Abstract][Full Text] [Related]
38. Bayesian adaptive D-optimal design with delayed responses. Li J; Fu H J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195 [TBL] [Abstract][Full Text] [Related]
39. Predicting event times in clinical trials when treatment arm is masked. Donovan JM; Elliott MR; Heitjan DF J Biopharm Stat; 2006 May; 16(3):343-56. PubMed ID: 16724489 [TBL] [Abstract][Full Text] [Related]